Does treating inflammation in the coronary arteries through medication actually make a difference for your long-term heart health?
Targeted anti-inflammatory treatment, particularly with low-dose colchicine, measurably reduces the risk of serious cardiac events in people with coronary artery disease. Discuss with your cardiologist whether this is relevant for you, because not every drug works and there are safety considerations that require careful weighing.
Even when bad cholesterol (LDL) is well controlled, a large proportion of patients with coronary artery disease still face an elevated risk of a heart attack. A considerable part of that risk comes from persistent low-grade inflammation in the vessel wall. That inflammation is also a strong predictor of recurrent cardiac events, even in people who are already receiving the best available medication.
Low-dose colchicine (0.5 mg per day) now has the most compelling results. After a recent heart attack, the risk of serious cardiac events fell by 23% compared with a placebo. In people with stable, chronic coronary artery disease, a large study (LoDoCo2) also showed a favourable long-term effect. Canakinumab, a drug that selectively blocks one specific inflammatory substance (interleukin-1 beta), reduced the risk of serious cardiac events by 15% in patients with an elevated inflammatory marker following a heart attack.
Not every anti-inflammatory drug works in heart disease. Low-dose methotrexate, a drug widely used in rheumatoid arthritis, was tested in a large randomised trial (CIRT) in patients with coronary artery disease and diabetes or weight problems. That trial was stopped early because no cardiac benefit whatsoever was found.
With colchicine there is a safety signal that deserves to be taken seriously: in some studies there was a potentially higher number of deaths from non-cardiac causes. This association has not yet been proven, but it shows that this type of treatment should not be started on your own initiative. Its use is therefore tailored to the individual patient. Despite the evidence for colchicine and canakinumab, anti-inflammatory agents have not yet been incorporated as standard into official treatment guidelines, meaning that practice still lags behind the available research.
Finally, the benefit varies from person to person. Patients with a measurably elevated inflammatory marker in their blood appear to benefit the most. Research into better selection criteria to determine who profits most is still ongoing.
All claims are based on reviews. The CANTOS, COLCOT, and LoDoCo2 studies are cited in multiple reviews as evidence of clinical effect; the CIRT study as evidence of absence of effect. No direct meta-analyses or original RCT reports are included in the source list.